Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HFE
REST API REST API
Homo sapiens
HFE is differentially expressed in 340 experiments: 184 organism parts: ovary, skin, ... (182 more);, 298 disease states: normal, breast carcinoma, ... (296 more);, 115 cell types 529 cell lines 50 compound treatments and 82 other conditions.
Synonyms HLA-H
Orthologs ENSGALG00000011014 (Gallus gallus)   CABZ01031754.1 (Danio rerio)   F1NH73_CHICK (Gallus gallus)   ENSGALG00000012967 (Gallus gallus)   F1N816_CHICK (Gallus gallus)   ENSGALG00000004617 (Gallus gallus)   mhc1ze (Danio rerio)   CABZ01089980.1 (Danio rerio)   ENSGALG00000000180 (Gallus gallus)   F1NS77_CHICK (Gallus gallus)   zgc:136614 (Danio rerio)   CABZ01029904.1 (Danio rerio)   mhc1uba (Danio rerio)   ENSGALG00000005825 (Gallus gallus)   Q5EEZ1_BOVIN (Bos taurus)   ENSGALG00000017674 (Gallus gallus)   si:ch211-287j19.6 (Danio rerio)   zgc:64115 (Danio rerio)   CABZ01031753.1 (Danio rerio)   Hfe (Mus musculus)   ENSGALG00000024427 (Gallus gallus)   F1NFX9_CHICK (Gallus gallus)   F1NKF8_CHICK (Gallus gallus)   F1NED2_CHICK (Gallus gallus)   F1NKE5_CHICK (Gallus gallus)   F1NM79_CHICK (Gallus gallus)   Hfe (Rattus norvegicus)   ENSXETG00000002125 (Xenopus laevis)   LOC100494930 (Xenopus laevis)   XB-GENE-5873924 (Xenopus laevis)   XB-GENE-5894693 (Xenopus laevis)   mhc1a (Xenopus laevis)   LOC100490553 (Xenopus laevis)   NP_001123818.1 (Xenopus laevis)   mhc1zel (Danio rerio)   LOC100490728 (Xenopus laevis)   ENSXETG00000030515 (Xenopus laevis)   LOC100487860 (Xenopus laevis)   si:ch73-213j4.4 (Danio rerio)   XB-GENE-5757686 (Xenopus laevis)   ENSXETG00000033980 (Xenopus laevis)   LOC100495225 (Xenopus laevis)   LOC100493954 (Xenopus laevis)   ENSXETG00000032875 (Xenopus laevis)   NP_001123671.1 (Xenopus laevis)   ENSXETG00000017938 (Xenopus laevis)   ENSXETG00000009068 (Xenopus laevis)   LOC100494293 (Xenopus laevis)   LOC100495868 (Xenopus laevis)   LOC100495703 (Xenopus laevis)   LOC100495542 (Xenopus laevis)   ENSXETG00000033834 (Xenopus laevis)   ENSXETG00000009089 (Xenopus laevis)   ENSXETG00000031111 (Xenopus laevis)   mr1 (Xenopus laevis)   HFE (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, basal part of cell, ion transport, membrane, receptor-mediated endocytosis, protein complex assembly, recycling endosome, iron ion transport, early endosome, cellular response to iron ion starvation, integral to plasma membrane, immune response, cytoplasmic vesicle, perinuclear region of cytoplasm, apical part of cell, integral to membrane, cellular iron ion homeostasis, female pregnancy, iron ion homeostasis, antigen processing and presentation of peptide antigen via MHC class I, MHC class I protein complex, hormone biosynthetic process, antigen processing and presentation, multicellular organismal iron ion homeostasis
InterPro Term Ig_C1-set, Ig-like, MHC_I_a_a1/a2
UniProt Accession Q96KU6, Q9UK37, Q6B0J5, Q86WL1, Q9HC69, Q30201, Q8MH46, Q9BXI5, F5B2M9, F5H4B0, F8W7W8
Gene-Disease Assocation PORPHYRIA CUTANEA TARDA, PORPHYRIA VARIEGATA, MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7, HEMOCHROMATOSIS; HFE, ALZHEIMER DISEASE; AD, TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; TFQTL2
Search EB-eye ENSG00000010704
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-62, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
Jurkat
1
2
E-MEXP-2197, E-GEOD-1880, E-MTAB-62
523 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (55 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
dendritic cell
2
E-MEXP-2019, E-GEOD-3982
CD8+ T cell
2
E-GEOD-6740, E-MTAB-25
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
2
E-TABM-145, E-AFMX-5
CD34+
2
E-AFMX-5, E-TABM-145
109 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, ... (76 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MTAB-62
control
3
E-GEOD-16363, E-GEOD-20602, E-GEOD-8121
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
neuroblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-1825
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-MEXP-1327
synovial sarcoma
2
E-GEOD-6481, E-MTAB-37
292 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
ethanol
2
E-MEXP-2241, E-GEOD-3113
resveratrol
1
E-TABM-782
BCR/ABL1
1
1
E-GEOD-15811
chloroguine
1
E-GEOD-5418
control - interferon-gamma
1
E-GEOD-7216
44 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
76
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-19246, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.3 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM